Patrys Ltd
ASX:PAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kingsemi Co Ltd
SSE:688037
|
CN |
|
Nevada Copper Corp
TSX:NCU
|
CA |
|
I
|
Izolacja Jarocin SA
WSE:IZO
|
PL |
|
P
|
Perseus Mining Ltd
OTC:PMNXF
|
AU |
|
A
|
Autodesk Inc
BMV:ADSK
|
US |
Patrys Ltd
Research & Development
Patrys Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Patrys Ltd
ASX:PAB
|
Research & Development
-AU$778.9k
|
CAGR 3-Years
52%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$60.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Research & Development
-AU$7.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$65m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
-36%
|
|
Patrys Ltd
Glance View
Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
See Also
What is Patrys Ltd's Research & Development?
Research & Development
-778.9k
AUD
Based on the financial report for Dec 31, 2025, Patrys Ltd's Research & Development amounts to -778.9k AUD.
What is Patrys Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
9%
Over the last year, the Research & Development growth was 74%. The average annual Research & Development growth rates for Patrys Ltd have been 52% over the past three years , 12% over the past five years , and 9% over the past ten years .
